These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 18488157)

  • 1. Thirty patients with primary plasma cell leukemia: a single center experience.
    Colović M; Janković G; Suvajdzić N; Milić N; Dordević V; Janković S
    Med Oncol; 2008; 25(2):154-60. PubMed ID: 18488157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.
    García-Sanz R; Orfão A; González M; Tabernero MD; Bladé J; Moro MJ; Fernández-Calvo J; Sanz MA; Pérez-Simón JA; Rasillo A; Miguel JF
    Blood; 1999 Feb; 93(3):1032-7. PubMed ID: 9920853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell leukemia: Clinicopathologic, immunophenotypic and cytogenetic characteristics of 4 cases.
    Alghasham N; Alnounou R; Alzahrani H; Alsharif F
    Hematol Oncol Stem Cell Ther; 2015 Jun; 8(2):71-7. PubMed ID: 25929729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary plasma cell leukemia: morphologic, immunophenotypic, and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation.
    Johnson MR; Del Carpio-Jayo D; Lin P; Giralt S; Anderlini P; Champlin RE; Khouri IF; Vadhan-Raj S; Medeiros LJ; Bueso-Ramos CE
    Ann Diagn Pathol; 2006 Oct; 10(5):263-8. PubMed ID: 16979517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma cell leukemia: a retrospective study of 10 cases.
    Agarwal AD; Brahmbhatt BS; Parikh BP; Shah MJ
    Indian J Cancer; 2014; 51(1):18-9. PubMed ID: 24947090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?
    Katodritou E; Verrou E; Gastari V; Hadjiaggelidou C; Terpos E; Zervas K
    Leuk Res; 2008 Jul; 32(7):1153-6. PubMed ID: 18083228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia.
    Bladé J; Kyle RA
    Hematol Oncol Clin North Am; 1999 Dec; 13(6):1259-72. PubMed ID: 10626149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aggressive primary plasma cell leukemia with skin manifestations, trisomy 8 and molecular oligoclonal features.
    Robak T; Urbańska-Rys H; Robak E; Bartkowiak J; Strzelecka B; Biernat W; Kordek R
    Leuk Lymphoma; 2002 May; 43(5):1067-73. PubMed ID: 12148888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significantly better prognosis for patients with primary plasma cell leukemia than for patients with secondary plasma cell leukemia.
    Cha CH; Park CJ; Huh JR; Chi HS; Suh CW; Kang YK
    Acta Haematol; 2007; 118(3):178-82. PubMed ID: 17934254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cell leukemia: Single institution experience.
    Babu KG; Jacob LA; Agarwal A; Lakshmaiah KC; Lokanatha D; Suresh Babu MC; Rajeev LK; Lokesh KN; Rudresha AH
    Indian J Cancer; 2016; 53(4):619-620. PubMed ID: 28485366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Necessity of flow cytometry assessment of circulating plasma cells and its connection with clinical characteristics of primary and secondary plasma cell leukaemia.
    Bezdekova R; Jelinek T; Kralova R; Stork M; Polackova P; Vsianska P; Brozova L; Jarkovsky J; Almasi M; Boichuk I; Knechtova Z; Penka M; Pour L; Sevcikova S; Hajek R; Rihova L
    Br J Haematol; 2021 Oct; 195(1):95-107. PubMed ID: 34500493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell leukemia: concepts and management.
    Liedtke M; Medeiros BC
    Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia.
    Tessier C; LeBlanc R; Roy J; Trudel S; Côté J; Lalancette M; Boudreault JS; Lemieux-Blanchard É; Kaedbey R; Pavic M
    Cancer Med; 2024 Sep; 13(17):e70192. PubMed ID: 39225552
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cell leukemia.
    Albarracin F; Fonseca R
    Blood Rev; 2011 May; 25(3):107-12. PubMed ID: 21295388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary plasma cell leukaemia: a report of 18 cases.
    Costello R; Sainty D; Bouabdallah R; Fermand JP; Delmer A; Diviné M; Marolleau JP; Gastaut JA; Olive D; Rousselot P; Chaïbi P
    Leuk Res; 2001 Feb; 25(2):103-7. PubMed ID: 11166824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunophenotype and DNA content of myeloma cells in primary plasma cell leukemia.
    Shimazaki C; Gotoh H; Ashihara E; Oku N; Inaba T; Murakami S; Itoh K; Ura Y; Nakagawa M; Fujita N
    Am J Hematol; 1992 Mar; 39(3):159-62. PubMed ID: 1546712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma.
    Colomo L; López-Guillermo A; Perales M; Rives S; Martínez A; Bosch F; Colomer D; Falini B; Montserrat E; Campo E
    Blood; 2003 Jan; 101(1):78-84. PubMed ID: 12393466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.